Real-World Evidence of Neuropsychiatric Adverse Reactions to Isotretinoin: Insights from EudraVigilance (2005–2025)
Pharmaceuticals · 24.08.2025 · 18 (9) · 1252
DOI: 10.3390/ph18091252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 24.08.2025. Verfasst von Denisa Viola Szilagyi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oradea, Oradea, Romania.
Abstract (Originalsprache)
Background/Objectives: Isotretinoin is a highly effective therapy for severe acne, but its potential neuropsychiatric adverse reactions (NPsRs) have been controversial. This study evaluated EudraVigilance data from 2005 to 2025 to better understand the frequency, typology, and predictors of such events.
Methods
We conducted a retrospective analysis of 33,381 individual case safety reports (ICSRs) related to isotretinoin. Using descriptive statistics, chi-square tests, and logistic regression, we assessed associations between NPsRs and variables such as age, sex, geographic region, and reporter type.
Results
A total of 9793 cases (29.3%) involved at least one NPsR. Depression (31%) and suicidal ideation (8.6%) were the most frequently reported symptoms. Adolescents (12–17 years) had the highest proportion of NPsR cases, while male patients and reports submitted by non-healthcare professionals were significantly overrepresented. Reports from non-European Economic Area countries also had slightly increased odds of including NPsRs. All predictors were statistically significant in the logistic regression model, though the explained variance was modest (Nagelkerke R2 = 0.065).
Conclusions
Neuropsychiatric reactions remain a prominent and persistent signal in isotretinoin pharmacovigilance, particularly among younger patients and non-professional reporters. Although causality cannot be inferred from spontaneous reporting data and confounding factors like acne-related depression cannot be excluded, these findings highlight the clinical value of pre-treatment psychiatric screening, patient-centered education, and proactive mental health monitoring throughout isotretinoin therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
- Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.
- Department of Morphology Sciences, University of Oradea, 410087 Oradea, Romania.
- Department of Psycho-Neurosciences and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
ORCID-Profile: Delia Mirela Tit, Claudia Teodora Judea-Pusta, Andrei-Flavius Radu, Ruxandra-Cristina Marin
Förderung
- University of Oradea, Oradea, Romania
Zitieren
APA
Szilagyi, D. V., Tit, D. M., Judea-Pusta, C. T., Radu, A. F., Bungau, G. S., Radu, A., Endres, L. M., & Marin, R. C. (2025). Real-World Evidence of Neuropsychiatric Adverse Reactions to Isotretinoin: Insights from EudraVigilance (2005–2025). Pharmaceuticals, 18(9), 1252. https://doi.org/10.3390/ph18091252
Vancouver
Szilagyi DV, Tit DM, Judea-Pusta CT, Radu AF, Bungau GS, Radu A, et al. Real-World Evidence of Neuropsychiatric Adverse Reactions to Isotretinoin: Insights from EudraVigilance (2005–2025). Pharmaceuticals. 2025;18(9):1252. doi:10.3390/ph18091252
BibTeX
@article{Szilagyi2025,
author = {Szilagyi, Denisa Viola and Tit, Delia Mirela and Judea-Pusta, Claudia Teodora and Radu, Andrei-Flavius and Bungau, Gabriela S and Radu, Ada and Endres, Laura Maria and Marin, Ruxandra-Cristina},
title = {Real-World Evidence of Neuropsychiatric Adverse Reactions to Isotretinoin: Insights from EudraVigilance (2005–2025)},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {9},
pages = {1252},
doi = {10.3390/ph18091252}
}
EUVIMED